company background image
PASG

Passage Bio NasdaqGS:PASG Stock Report

Last Price

US$1.16

Market Cap

US$63.3m

7D

-4.1%

1Y

-83.8%

Updated

05 Dec, 2022

Data

Company Financials +
PASG fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PASG Stock Overview

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases.

Passage Bio, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Passage Bio
Historical stock prices
Current Share PriceUS$1.16
52 Week HighUS$7.77
52 Week LowUS$1.11
Beta1.14
1 Month Change-6.45%
3 Month Change-38.95%
1 Year Change-83.78%
3 Year Changen/a
5 Year Changen/a
Change since IPO-94.77%

Recent News & Updates

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Nov 13
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Passage appoints William Chou CEO

Oct 10

Recent updates

Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

Nov 13
Is Passage Bio (NASDAQ:PASG) In A Good Position To Deliver On Growth Plans?

We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Jun 03
We're A Little Worried About Passage Bio's (NASDAQ:PASG) Cash Burn Rate

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Dec 15
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

Aug 19
Passage Bio (NASDAQ:PASG) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Mar 08
We're Hopeful That Passage Bio (NASDAQ:PASG) Will Use Its Cash Wisely

Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Feb 01
Do Institutions Own Passage Bio, Inc. (NASDAQ:PASG) Shares?

Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

Dec 28
Need To Know: Passage Bio, Inc. (NASDAQ:PASG) Insiders Have Been Buying Shares

Shareholder Returns

PASGUS BiotechsUS Market
7D-4.1%4.2%1.5%
1Y-83.8%-7.4%-14.9%

Return vs Industry: PASG underperformed the US Biotechs industry which returned -7.4% over the past year.

Return vs Market: PASG underperformed the US Market which returned -14.9% over the past year.

Price Volatility

Is PASG's price volatile compared to industry and market?
PASG volatility
PASG Average Weekly Movement10.5%
Biotechs Industry Average Movement11.2%
Market Average Movement7.4%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market3.3%

Stable Share Price: PASG is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: PASG's weekly volatility (11%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017133William Chouhttps://www.passagebio.com

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A.

Passage Bio, Inc. Fundamentals Summary

How do Passage Bio's earnings and revenue compare to its market cap?
PASG fundamental statistics
Market CapUS$63.28m
Earnings (TTM)-US$160.21m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PASG income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$160.21m
Earnings-US$160.21m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.94
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did PASG perform over the long term?

See historical performance and comparison